BRAF V600E in adult-type glioblastoma is rare (~1-3%) but more common in epithelioid GBM...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-GBM |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GBM |
| Sources | SRC-CIVIC SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-GBM |
| ESCAT tier | IIIA |
| Recommended combinations | dabrafenib + trametinib (recurrent / progressive after RT + TMZ) |
| Contraindicated monotherapy | vemurafenib monotherapy (limited CNS penetration, paradoxical RAS-RAF activation in BRAF-WT clones) |
| Evidence summary | BRAF V600E in adult-type glioblastoma is rare (~1-3%) but more common in epithelioid GBM and pediatric high-grade glioma. Dabrafenib + trametinib is tissue-agnostic FDA-approved (2022) for BRAF V600E solid tumors after progression on prior therapy — covers BRAF V600E GBM (Wen et al. ROAR-glioma 2022, ORR 33% in HGG). Vorasidenib does NOT apply here (IDH-mutant only). |
Notes
ESCAT IIIA. OncoKB Level 2 (tissue-agnostic). Reflex BRAF V600E testing recommended for epithelioid GBM and pediatric/AYA HGG. Distinct from low-grade pediatric glioma where BRAFi has stronger evidence.
Used By
No reverse references found in the YAML corpus.